Global Leading Market Research Publisher QYResearch announces the release of its latest report *“Laser Treatment Devices for BPH – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”*. Based on current market conditions, historical impact analysis (2021-2025), and forecast calculations (2026-2032), this report delivers a comprehensive evaluation of the global laser treatment devices for benign prostatic hyperplasia (BPH) market—encompassing market size, share, demand dynamics, industry development status, and forward-looking projections essential for medical device manufacturers, urology department administrators, hospital procurement executives, and healthcare investors.
The global market for laser treatment devices for BPH was valued at an estimated US$711 million in 2025 and is projected to reach US$1,307 million by 2032, expanding at a robust CAGR of 9.1% over the forecast period. Global shipment volume reached approximately 4,900 systems in 2025, with an average global selling price of approximately US$145,000 per unit. The industry typically maintains gross profit margins ranging from 45% to 65%, supported by clinical efficacy advantages, reduced complication rates, shorter hospital stays, and long equipment replacement cycles. This accelerated growth reflects aging male populations worldwide, increasing awareness of minimally invasive surgical options, and favorable clinical outcomes that position laser-based techniques as preferred alternatives to traditional transurethral resection of the prostate (TURP).
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/5706966/laser-treatment-devices-for-bph
Defining Laser Treatment Devices for BPH
Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland affecting aging men, leading to lower urinary tract symptoms (LUTS) including urinary frequency, urgency, weak stream, and incomplete bladder emptying. Laser treatment devices for BPH are minimally invasive surgical systems that use laser energy to ablate, vaporize, or enucleate enlarged prostate tissue, relieving urethral obstruction and restoring normal urinary flow.
These systems operate through several laser-tissue interaction mechanisms:
- Vaporization: High-power laser energy directly converts prostate tissue into gas, creating an immediate通道 (channel) through the prostate
- Enucleation: The laser dissects and separates adenomatous tissue from the surgical capsule, allowing morcellation and removal of large tissue volumes
- Ablation: Lower-power laser energy coagulates and necroses tissue, which is subsequently reabsorbed or sloughed
The supply chain encompasses upstream components including laser sources (holmium:YAG, thulium fiber, diode), optical delivery fibers, control electronics, cooling systems, and disposable accessories. Midstream manufacturers focus on system integration, clinical validation, regulatory approval, and physician training. Downstream users include hospitals, specialized urology centers, and ambulatory surgery centers.
Clinical Advantages Over Traditional TURP
The laser treatment devices for BPH market derives its growth from several clinical advantages that distinguish laser techniques from TURP, the historical gold standard.
Reduced bleeding risk represents the most significant advantage. Laser procedures coagulate blood vessels during tissue ablation, resulting in minimal intraoperative blood loss. This enables treatment of patients on anticoagulant therapy (warfarin, clopidogrel, apixaban, rivaroxaban)—a population previously considered high-risk for TURP. With the aging population and increasing prevalence of cardiovascular disease requiring anticoagulation, this capability expands the treatable patient pool substantially.
Shorter catheterization time and hospital stay improve resource utilization and patient satisfaction. Many laser procedures achieve same-day or next-day catheter removal, compared to 1–3 days following TURP. Hospital stays of 1–2 days versus 3–5 days for TURP reduce healthcare costs and increase surgical suite throughput.
Reduced complication rates include lower incidence of transurethral resection syndrome (a potentially serious complication from fluid absorption), reduced postoperative bleeding requiring transfusion, and lower rates of postoperative incontinence and erectile dysfunction for certain laser techniques.
Durable outcomes comparable to TURP have been demonstrated in long-term studies for holmium laser enucleation of the prostate (HoLEP), which achieves complete tissue removal with low reoperation rates.
Procedure Segmentation: HoLEP, HOLAP, and PVP
The laser treatment devices for BPH market is segmented by surgical technique into holmium laser enucleation of the prostate (HoLEP) , holmium laser ablation of the prostate (HOLAP) , and photoselective vaporization of the prostate (PVP) .
Holmium laser enucleation of the prostate (HoLEP) represents the fastest-growing segment, with a projected CAGR of 10.2% through 2032. HoLEP uses a holmium:YAG laser to dissect and enucleate entire adenoma lobes, which are then morcellated and removed. The technique offers:
- Size-independent efficacy: Effective for prostates of any size, including very large glands (>100g) where TURP is challenging
- Complete tissue removal: Low reoperation rates (1–2% at 5 years)
- Gold standard status: Preferred by many urologists for large prostates and academic centers
Photoselective vaporization of the prostate (PVP) uses a potassium-titanyl-phosphate (KTP) or lithium triborate (LBO) laser to vaporize prostate tissue. Advantages include:
- Excellent hemostasis: Minimal bleeding even in anticoagulated patients
- Rapid symptom relief: Immediate improvement in urinary flow
- Outpatient potential: Many PVP procedures performed as same-day surgery
Holmium laser ablation of the prostate (HOLAP) represents a smaller segment, as HoLEP has largely superseded HOLAP for patients requiring tissue removal.
Product Segmentation: Fixed and Removable Systems
The market is segmented by device configuration into fixed type and removable type systems.
Fixed type systems are permanently installed in operating rooms or urology suites, typically offering higher power output (100–120W) and more advanced features including multiple wavelengths and integrated morcellators. These systems dominate hospital-based procedures, particularly HoLEP which requires morcellation capability.
Removable type systems are mobile units that can be transported between procedure rooms or facilities. These systems serve ambulatory surgery centers, smaller hospitals, and clinics where dedicated fixed systems are not economically justified.
Market Drivers: Aging Male Demographics, Minimally Invasive Preference, and Anticoagulant Compatibility
The laser treatment devices for BPH market is propelled by three structural drivers.
First, aging male populations globally expand the addressable patient pool. BPH prevalence increases with age, affecting approximately 50% of men aged 50–60 and 80–90% of men over 70. As life expectancy increases and populations age across North America, Europe, and Asia-Pacific, the number of men requiring treatment for symptomatic BPH continues to grow.
Second, increasing awareness of minimally invasive procedures influences patient and referring physician preferences. Patients increasingly seek procedures with shorter recovery times, less postoperative pain, and reduced complication risk. Laser techniques satisfy these preferences while achieving outcomes equivalent or superior to TURP.
Third, anticoagulant compatibility addresses a critical unmet need. An estimated 30–40% of men requiring BPH surgery have cardiovascular conditions requiring anticoagulation. Traditional TURP carries prohibitive bleeding risk in this population, often forcing deferral of surgery or temporary discontinuation of anticoagulation (which increases thromboembolic risk). Laser procedures enable safe treatment without anticoagulation interruption.
Competitive Landscape
The laser treatment devices for BPH market features a competitive landscape with established medical device companies and specialized laser manufacturers. Key players profiled in the report include Boston Scientific, Endo Pharmaceuticals, KARL STORZ SE & Co. KG, Lumenis, Olympus, Urologix, LISA Laser USA, ProArc Medical, Urovision-Urotech, Teleflex Incorporated, Richard Wolf GmbH, BD (Becton, Dickinson and Company) , Biolitec AG, Coloplast Corp, Dornier MedTech, Quanta System, Asclepion Laser Technologies, and El.En. Group.
The competitive landscape is characterized by:
- Wavelength differentiation: Holmium (2100nm) dominates enucleation; thulium fiber (1940nm) offers continuous-wave operation; KTP/LBO (532nm) provides selective absorption in hemoglobin for vaporization
- Clinical evidence accumulation: Manufacturers with published long-term outcomes, randomized trials, and health economic analyses command premium positioning
- Physician training programs: Comprehensive proctoring and certification programs drive adoption and loyalty
- Regulatory approvals: CE marking, FDA clearance, and regional approvals across major markets are essential for global distribution
Market Challenges: Capital Cost, Training Requirements, and Reimbursement
The laser treatment devices for BPH market faces several challenges. High capital cost (US$100,000–200,000 per system) limits adoption in smaller facilities and price-sensitive markets, despite favorable lifetime cost-effectiveness compared to TURP when accounting for reduced complications and shorter hospital stays.
Training requirements for HoLEP, in particular, present a steep learning curve (30–50 cases to achieve proficiency), limiting procedure volume and adoption rates. Manufacturers offering structured training programs gain competitive advantage.
Reimbursement variability across regions affects adoption. Established reimbursement for laser procedures in North America and Western Europe supports market growth; emerging markets may lack dedicated reimbursement codes or adequate payment levels.
Regional Dynamics: North America Leads, Asia-Pacific Accelerates
North America remains the largest regional market, driven by aging population, high healthcare spending, established reimbursement, and early adoption of HoLEP as standard of care. Europe follows, with strong markets in Germany, the UK, France, and Italy. Asia-Pacific represents the fastest-growing region, with a projected CAGR of 10.8% through 2032, driven by aging populations in Japan, China, and South Korea, expanding healthcare infrastructure, and increasing adoption of minimally invasive techniques.
Conclusion
The laser treatment devices for BPH market is positioned for accelerated double-digit growth through 2032, driven by aging male populations, preference for minimally invasive procedures, and the unique advantages of laser techniques including reduced bleeding risk and anticoagulant compatibility. Success in this market requires manufacturers to invest in clinical evidence generation, physician training programs, and regulatory approvals while differentiating across laser wavelengths and procedure-specific capabilities. The report *“Laser Treatment Devices for BPH – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”* provides the granular segmentation analysis, competitive intelligence, and forward-looking forecasts essential for stakeholders navigating this dynamic urology device sector.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
